Stock Evaluator: Immuneering Corporation (IMRX)

Immuneering Corporation IMRX

$3.50 0.04 1.16%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 730,703
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics IMRX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $226.7 $213.9 30%
Shares Out (Mil) 64.7 55.4 53%
Institutional Ownership 77.9% 93.3% 47%
Float (Mil) 49.3 40.6 46%
Beta 0.46 0.98 25%
Avg Daily Volume (000s) 783 597 65%
Price Change
(52-week)
(49.4%) 40.9% 20%
Growth IMRX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (26.9%) (10.7%) 16%
EPS (5yr) 18.0% 15.5% 65
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (14.9%) (15.7%) 53%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 7 7 7
Current EPS ($0.407) ($1.257) ($1.641)
Month Ago EPS ($0.339) ($1.119) ($1.256)
# Rev Up 2 0 0
# Rev Down 0 1 1
Three Months Ago EPS ($0.343) ($1.120) ($1.271)
Year/Year Chg 8.8% (1.3%) 35.3%
Financials IMRX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($67) ($44) 14%
EPS (TTM) ($1.028) ($1.400) 20%
Operating Cash Flow (TTM) (Mil) ($62) ($34) 9%
Net Cash Flow (TTM) (Mil) ($169) $-0 11%
Long-Term Debt (Q1) (Mil) $3 $4 22%
Enterprise Value (Q1) (Mil) $80 $135 21%
Valuation IMRX Industry
Median
Percentile
(All Stocks)
P/B 1.35 1.97 40%
P/E na 17.6 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios IMRX Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.8%) na
ROA (31.4%) (47.5%) 16%
ROE (33.5%) (51.9%) 19%
Liabilities to Assets 7.6% 29.7% 4%
F-Score 3 3 18%

Passing Stock Screens

As of 11/18/2026, from a list of 60 stock screening strategies, IMRX meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors